Lifeloc Technologies, Inc (LCTC) Form 8-K — Aug 14, 2026
Lifeloc Technologies (OTCID: LCTC) reported second-quarter 2026 revenue of $2.445 million, up 10% year over year, and cut its net loss to $134 thousand ($0.05 per diluted share) from $394 thousand ($0.14) a year earlier. Gross margin rose to 45% from 42%, helped by price increases and a favorable product mix. The company said it has completed the SpinDetect microfluidic disk design for its centrifugal drug analyzer and will begin beta testing focused on delta-9-THC oral-fluid detection, targeting a limited commercial launch in Q1 2027.
Key figures
- Revenue
- 2444957
- Revenue Yoy
- 10%
- Total Assets
- 7078907
- Cash Position
- 908208
- Shares Outstanding
- 2752616
- Rd Expense Q2
- 560281
- Gross Margin Q2
- 45%
- Six Month Revenue
- 4738769
- Total Liabilities
- 3262172
- Prior Year Q2 Revenue
- 2219376
- Stockholders Equity
- 3816735
- Gross Margin Six Month
- 44%
- Related Party Loan Rate
- 10.5%
- Gross Margin Prior Year Q2
- 42%
- Related Party Loan Amount
- 500000
AI analysis
Red flags5 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.